Trials / Completed
CompletedNCT00443170
A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects
A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a first time in human study to investigate the safety of GSK626616AC given as oral single and repeat doses in healthy subjects. An additional group of subjects will be assessed to determine the effect of several drugs given at the same time as GSK626616.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK626616, placebo, midazolam | |
| DRUG | omeprazole, caffeine, flurbiprofen, rosiglitazone |
Timeline
- Start date
- 2006-11-01
- First posted
- 2007-03-05
- Last updated
- 2012-03-19
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00443170. Inclusion in this directory is not an endorsement.